Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20

Solid Biosciences Inc.

Solid Biosciences Inc.

SLDB

0.00

Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ: SLDB) with a Buy and raises the price target from $16 to $20.